DNA Logo

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Forecast & Price Prediction

Live DNA Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Biotechnology

$13.52

-0.73 (-5.12%)

12 Month Price Forecast For DNA

$13.52
Current Price
$777.11M
Market Cap
6 Ratings
Buy 1
Hold 1
Sell 4
Wall St Analyst Ratings

Distance to DNA Price Forecasts

+18.3%
To High Target of $16.00
-40.8%
To Median Target of $8.00
-55.6%
To Low Target of $6.00

DNA Price Momentum

-5.4%
1 Week Change
+38.2%
1 Month Change
-76.0%
1 Year Change
+37.7%
Year-to-Date Change
-79.0%
From 52W High of $64.40
+157.0%
From 52W Low of $5.26

๐Ÿค” Considering Ginkgo Bioworks (DNA)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 6:32 AM UTC

DNA Analyst Ratings & Price Targets

Based on our analysis of 11 Wall Street analysts, DNA has a bearish consensus with a median price target of $8.00 (ranging from $6.00 to $16.00). Currently trading at $13.52, the median forecast implies a -40.8% downside. This outlook is supported by 1 Buy, 1 Hold, and 4 Sell ratings.

Conversely, the most conservative target is provided by Gaurav Goparaju at Berenberg, suggesting a 55.6% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

DNA Analyst Consensus

1
Buy
1
Hold
4
Sell

DNA Price Target Range

Low
$6.00
Average
$8.00
High
$16.00
Current: $13.52

Latest DNA Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for DNA.

Date Firm Analyst Rating Change Price Target
Sep 20, 2024 TD Cowen Brendan Smith Buy Maintains $10.00
Aug 23, 2024 BTIG Mark Massaro Sell Maintains $7.00
Jul 9, 2024 Goldman Sachs Matthew Sykes Sell Maintains $0.30
Jun 26, 2024 BTIG Mark Massaro Sell Maintains $0.20
May 15, 2024 BTIG Mark Massaro Sell Downgrade $0.00
May 15, 2024 Morgan Stanley Tejas Savant Equal-Weight Maintains $1.00
May 10, 2024 William Blair Matt Larew Underperform Downgrade $0.00
Mar 1, 2024 TD Cowen Steven Mah Outperform Maintains $3.00
Jan 23, 2024 Goldman Sachs Matthew Sykes Sell Maintains $1.10
Jan 22, 2024 Goldman Sachs Matthew Sykes Sell Maintains $1.10
Nov 15, 2023 Raymond James Rahul Sarugaser Market Perform Downgrade $2.50
Nov 14, 2023 Raymond James Rahul Sarugaser Market Perform Downgrade $2.50
Nov 9, 2023 BTIG Mark Massaro Neutral Downgrade $0.00
Jun 5, 2023 Goldman Sachs Matthew Sykes Sell Maintains $1.25
Jun 2, 2023 Goldman Sachs Matthew Sykes Sell Downgrade $1.25
May 11, 2023 William Blair Matt Larew Market Perform Downgrade $0.00
Nov 29, 2022 Berenberg Gaurav Goparaju Buy Initiates $6.00
Oct 4, 2022 Morgan Stanley Tejas Savant Equal-Weight Initiates $5.00
Aug 16, 2022 BTIG Mark Massaro Buy Maintains $6.00
Aug 16, 2022 Raymond James Rahul Sarugaser Outperform Maintains $14.50

Stocks Similar to Ginkgo Bioworks Holdings, Inc.

The following stocks are similar to Ginkgo Bioworks based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Ginkgo Bioworks Holdings, Inc. (DNA) Financial Data

Ginkgo Bioworks Holdings, Inc. has a market capitalization of $777.11M with a P/E ratio of -0.7x. The company generates $217.95M in trailing twelve-month revenue with a -298.8% profit margin.

Revenue growth is +60.6% quarter-over-quarter, while maintaining an operating margin of -58.7% and return on equity of -63.5%.

Valuation Metrics

Market Cap $777.11M
Enterprise Value $605.70M
P/E Ratio -0.7x
PEG Ratio -1.7x
Price/Sales 3.6x

Growth & Margins

Revenue Growth (YoY) +60.6%
Gross Margin +86.4%
Operating Margin -58.7%
Net Margin -298.8%
EPS Growth +59.1%

Financial Health

Cash/Price Ratio +83.7%
Current Ratio 5.8x
Debt/Equity 55.8x
ROE -63.5%
ROA -20.9%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Ginkgo Bioworks Holdings, Inc. logo

Ginkgo Bioworks Holdings, Inc. (DNA) Company Overview

About Ginkgo Bioworks Holdings, Inc.

What They Do

Develops cell programming platforms for biotechnology.

Business Model

The company operates a platform that programs cells to produce various biological products, including therapeutics, food ingredients, and chemicals. It generates revenue by serving a diverse range of industries such as pharmaceuticals, agriculture, and consumer technology.

Additional Information

Founded in 2008 and headquartered in Boston, Ginkgo Bioworks is positioned at the intersection of biotechnology and synthetic biology, targeting applications that address global challenges in health, food, and environmental sustainability.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

1,218

CEO

Dr. Jason Kelly Ph.D.

Country

United States

IPO Year

2021

Ginkgo Bioworks Holdings, Inc. (DNA) Latest News & Analysis

DNA stock latest news image
Quick Summary

Ginkgo Bioworks (NYSE: DNA) will host the 2025 Ferment Series, an evolution of its annual conference, aiming to advance its mission in cell programming and biosecurity in Boston's Seaport District.

Why It Matters

The Ferment conference highlights Ginkgo Bioworks' commitment to innovation in biotechnology, potentially driving investor interest and confidence in its growth and market position.

Source: PRNewsWire
Market Sentiment: Neutral
DNA stock latest news image
Quick Summary

Ginkgo Bioworks (DNA) saw increased trading volume recently, but recent earnings estimate revisions may hinder its short-term upward momentum.

Why It Matters

Ginkgo Bioworks' significant trading volume indicates heightened interest, but negative earnings estimate revisions could signal potential declines, affecting investor sentiment and future stock performance.

Source: Zacks Investment Research
Market Sentiment: Positive
DNA stock latest news image
Quick Summary

Ginkgo Bioworks (DNA) has received a Zacks Rank #1 (Strong Buy) upgrade, indicating increasing optimism about its earnings prospects.

Why It Matters

Ginkgo Bioworks' upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving stock price upward.

Source: Zacks Investment Research
Market Sentiment: Positive
DNA stock latest news image
Quick Summary

Ginkgo Bioworks will design an anaerobic lab automation system for the University of Wisconsin's GLBRC to enhance biofuel research, supporting multiple teams in biomass conversion.

Why It Matters

Ginkgo Bioworks' new automation system enhances biofuel research efficiency, potentially leading to faster innovations and market readiness in sustainable energy, impacting future growth and profitability.

Source: PRNewsWire
Market Sentiment: Neutral
DNA stock latest news image
Quick Summary

SaponiQx has partnered with Probius and Ginkgo Bioworks, funded by DTRA, to enhance saponin-based adjuvant discovery and development for chemical and biological defense.

Why It Matters

The collaboration enhances innovation in biotechnology, potentially leading to breakthroughs in drug development, impacting market competitiveness and long-term growth prospects for involved companies.

Source: Business Wire
Market Sentiment: Neutral
DNA stock latest news image
Quick Summary

Ginkgo Bioworks (NYSE: DNA) partners with Universal Cells to enhance iPSC-derived cancer therapies using its cell engineering platform, focusing on solid tumor treatments.

Why It Matters

The collaboration enhances Ginkgo Bioworks' position in biotech, potentially increasing its market value and attracting investor interest due to advancements in cancer therapies.

Source: PRNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About DNA Stock

What is Ginkgo Bioworks Holdings, Inc.'s (DNA) stock forecast for 2025?

Based on our analysis of 11 Wall Street analysts, Ginkgo Bioworks Holdings, Inc. (DNA) has a median price target of $8.00. The highest price target is $16.00 and the lowest is $6.00.

Is DNA stock a good investment in 2025?

According to current analyst ratings, DNA has 1 Buy ratings, 1 Hold ratings, and 4 Sell ratings. The stock is currently trading at $13.52. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for DNA stock?

Wall Street analysts predict DNA stock could reach $8.00 in the next 12 months. This represents a -40.8% decrease from the current price of $13.52. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Ginkgo Bioworks Holdings, Inc.'s business model?

The company operates a platform that programs cells to produce various biological products, including therapeutics, food ingredients, and chemicals. It generates revenue by serving a diverse range of industries such as pharmaceuticals, agriculture, and consumer technology.

What is the highest forecasted price for DNA Ginkgo Bioworks Holdings, Inc.?

The highest price target for DNA is $16.00 from at , which represents a 18.3% increase from the current price of $13.52.

What is the lowest forecasted price for DNA Ginkgo Bioworks Holdings, Inc.?

The lowest price target for DNA is $6.00 from Gaurav Goparaju at Berenberg, which represents a -55.6% decrease from the current price of $13.52.

What is the overall DNA consensus from analysts for Ginkgo Bioworks Holdings, Inc.?

The overall analyst consensus for DNA is bearish. Out of 11 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 4 as Sell, with a median price target of $8.00.

How accurate are DNA stock price projections?

Stock price projections, including those for Ginkgo Bioworks Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.